Does spironolactone reduce albuminuria and blood pressure in type 2 diabetic patients with nephropathy?
Adding spironolactone to maximal ACEi/ARB therapy reduces albuminuria and blood pressure in patients with type 2 diabetes and nephropathy.
Our study suggests that spironolactone safely adds to the reno- and cardiovascular protective benefits of treatment with maximally recommended doses of ACE inhibitor and ARB by reducing albuminuria and blood pressure in type 2 diabetic patients with nephropathy.
Rossing et al. (Thu,) studied this question.